

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

VEECH, Richard L.

Atty. Ref.: 604-707

Serial No. Unassigned

Group: Unassigned

Filed: January 26, 2004

Examiner: Unassigned

For: THERAPEUTIC COMPOSITIONS

* * * * *

January 26, 2004

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT


Attached is a completed Form PTO-1449 listing references in connection with this application. Copies of these references are in the file-wrapper of parent application Serial No. 10/408,667 and are therefore not being submitted with this IDS.

The Examiner is requested to initial the attached PTO-1449, and to return a copy of the initialed document to the undersigned as an indication that the listed references have been considered and made of record.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009

LCM:lfm
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

604-707

Unassigned

APPLICANT

VEECH, Richard L.

(Use several sheets if necessary)

FILING DATE

GROUP

January 26, 2004

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,579,955	04/1986	Lammerant et al			02/22/83
	4,771,074	09/1988	Lammerant et al			10/23/88
	4,067,999	01/10/78	Glabe et al			05/02/77
	4,351,835	09/1982	Stanko			04/01/81
	4,363,815	12/1982	Yu et al			04/30/80
	5,348,979	09/1994	Nissen et al			12/23/92
	5,719,119	02/1998	Veech			04/26/93
	5,654,266	08/1997	Chen et al			03/28/94
	5,292,774	03/1994	Hiraide et al			04/27/93
	4,997,976	03/1991	Brunengraber et al			11/15/88
	5,126,373	01/1992	Brunengraber et al			12/06/90
	5,116,868	05/1992	Chen et al			05/03/89
	4,346,107	08/1982	Cavazza et al			02/09/80
	4,929,449	05/29/90	Veech			12/17/86
	5,200,200	04/1993	Veech			04/16/90
	5,912,269	01/1999	Tung			04/30/96
	5,100,677	03/1992	Veech			12/17/86
	4,983,766	01/1991	Imwinkelried et al			12/23/88
	4,970,143	11/1990	Guidoux et al			08/14/86
	4,701,443	10/1987	Nelson et al			03/22/83
	5,693,850	12/1997	Birkhahn et al			06/06/95
	4,234,599	11/1980	Van Scott et al			04/10/78
	4,211,846	07/1980	Lafferty			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
0780123	11/1996	EP			
0562188	03/1992	EP			
0318357	11/1988	EP			
WO 98/51812	05/1998	PCT			
WO 99/34687	01/1999	PCT			
0108820	11/1982	EP			
0288908	04/1988	EP			
0466050	07/1991	EP			
WO 92/09211	11/1991	PCT			
WO 92/09210	11/1991	PCT			
WO 98/41201	03/1998	PCT			
0552896	01/1993	EP			
2126082	08/1982	GB			

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	604-707	Unassigned
(Use several sheets if necessary)	APPLICANT	
	VEECH, Richard L.	
	FILING DATE	GROUP
	January 26, 2004	Unassigned

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	"Biopolymers and -oligomers of (R)-3-Hydroxyalkanoic Acids - Contributions of synthetic Organic Chemists": D Seebach et al; Ernst Schering Research Foundation; 1995.
	"Biodegradation of cyclic and substituted linear oligomers of poly(3-hydroxybutyrate)": Helmut Brandl et al; Can. J. Microbiol 41(Suppl. 1); 1995; Pages 180-186.
	"Direct degradation of the biopolymer poly[(R)-3-hydroxybutyric acid] to (R)-3-hydroxybutanoic acid and its methyl ester"; D Seebach et al; Org. Synth. 71; 1992; Pages 39-47.
	"Cyclische Oligomere von (R)-3-Hydroxybuttersäure: Herstellung und strukturelle Aspekte"; von Dietmar et al; Helvetica Chimica Acta: Vol 76; 1993; Pages 2004-2016.
	"Poly(hydroxyalkanoates): A Fifth Class of Physiologically Important Organic Biopolymers?"; Hans-Martin Muller et al; Angew. Chem.; 1993.
	"Intractable epilepsy"; Avinoam Scuper et al; The Lancet, Vol 353; April 10, 1999; Page 1238.
	"Energy Metabolism and the Regulation of Metabolic Processes in Mitochondria"; R.L. Veech et al; Academic Press; 1972; Pages 170-183.
	"Nontoxic Amyloid β Peptide ₁₋₄₂ suppresses Acetylcholine synthesis"; Minako Hoshi et al; The Journal of Biological Chemistry; Vol. 272, No. 4; January 1997; Pages 2038-2041.
	"Alternate Fuel Utilization by Brain"; George F. Cahill Jr. et al; Cerebral Metabolism and Neural Function; Williams Wilkins, London; Pages 234-242.
	"Preparation and Structure of Oligolides from (R)-3-Hydroxypentanoic Acid and comparison with the Hydroxybutanoic-Acid Derivatives: A Small Change with Large Consequences"; Dieter Seebach et al; Helvetica Chimica Acta - Vol. 77; 1994; Pages 2007 - 2033.
	"The Triolide of (R)-3-Hydroxybutyric acid - Direct Preparation from Polyhydroxybutyrate and Formation of a Crown Ester-carbonyl Complex with Na Ions"; Dieter Seebach et al; Angew. Chem. Int.; 1992; Pages 434-435.
	"Ketone bodies as substrates"; A.J. Rich; Proceedings of the Nutrition Society, Vol. 49; 1990; Pages 361-373.
	"The Dimer and Trimer of 3-Hydroxybutyrate Oligomer as a Precursor of Ketone Bodies for Nutritional Care"; Osamu Tasaki et al; Journal of Parenteral and Enteral Nutrition, Vol. 23, No. 6; 1999; Pages 321-325.
	"Effect of 3-hydroxybutyrate in obese subjects on very-low-energy diets and during therapeutic starvation"; G.L.S. Pawan et al; The Lancet; January 1983; Pages 15-17.
	"The untoward effects of the anions of dialysis fluids"; R.L. Veech et al; Kidney international, Vol. 34; 1988; Pages 587-597.
	"Transport of poly- β -hydroxybutyrate in human plasma"; Rosetta N. Reusch et al; Biochimica et Biophysica Acta 1123; 1992; Pages 33-40.
	"Human xenobiotic metabolizing esterases in liver and blood"; N.W. McCracken et al; Biochemical Pharmacology Vol. 46, No. 7; 1993; Pages 1125-1129.
	"Detection, synthesis, structure, and function of oligo(3-hydroxyalkanoates): contributions by synthetic organic chemists"; Dieter Seebach et al; International Journal of Biological Macromolecules 25; 1999; Pages 217-236.
	"Poly(hydroxyalkanoates): A Fifth Class of Physiologically Important Organic Biopolymers?" Hans-Martin Muller et al; Angewandte Chemie Vol. 32, No. 4; April 1993; Pages 477-502.
	"The toxic impact of parenteral solutions on the metabolism of cells: a hypothesis for physiological parenteral therapy"; R.L. Veech et al; The American Journal of Clinical Nutrition 44; October 1986; Pages 519-551.
	"Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study"; Johanna Kuusisto et al; BMJ Vol. 315; 25 October 1997; Pages 1045-1049.
	"Novel calcium ion channel is a pore without protein"; Karen Hopkin; The Journal of NIH Research Vol. 9; November 1997; Pages 25-26.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	604-707	Unassigned
	APPLICANT	
(Use several sheets if necessary)	VEECH, Richard L.	
	FILING DATE	GROUP
	January 26, 2004	Unassigned

	"Physiological Roles of Ketone Bodies as Substrates and Signals in Mammalian Tissues"; Alison M. Robinson et al; Physiological Reviews; Vol. 60, No. 1; January 1980; Pages 143-153.
	"Proof for a nonproteinaceous calcium-selective channel in <i>Escherichia coli</i> by total synthesis from (R)-3-hydroxybutanoic acid and inorganic polyphosphate"; Sudipto Das et al; Proc. Natl. Acad. Sci. USA; Vol. 94; August 1997; Pages 9075-9079.
	"New clues to Alzheimer's disease: Unraveling the roles of amyloid and tau"; Bruce A. Yankner; Nature Medicine Vol. 2, No. 8; August 1996; Pages 850-852.
	"An intracellular protein that binds amyloid- β peptide and mediates neurotoxicity in Alzheimer's disease"; Shi Du Yan et al; Nature, Vol. 389; 16 October 1997; Pages 689-695.
	"Alternate Fuel Utilization by Brain"; George F. Cahill, Jr. et al; Cerebral Metabolism and Neural Function; Williams & Wilkins; Chapter 26, Pages 234-242.
	"Blood-Brain Barrier Transport of Metabolic Substrates"; William H. Oldendorf; Cerebral Metabolism and Neural Function; Williams & Wilkins; Chapter 15, Pages 127-132.
	" β -hydroxybutyrate suppresses pentylenetetrazol (PTZ) - induced seizures in young adult rats"; Sarah Lustig et al; Epilepsia, Vol. 39, Suppl. 6; 1998; 2.020; Page 36.
	" β -hydroxybutyrate potentiates gaba _A -mediated inhibitory postsynaptic potentials in immature hippocampal CA1 neurons"; Shundi Ge et al; Epilepsia, Vol. 39, Suppl. 6; 1998; E.06; Page 135.
	"The effect of ketone bodies, β -hydroxybutyrate, and acetoacetate on acute seizure activity in hippocampal CA1 neurons"; Charles E. Niesen et al; Epilepsia, Vol. 39, Suppl. 6; 1998; 2.015; Pae 35.
	"Biologica-Chemical preparation of 3-hydroxycarboxylic acids and their use in EPC-synthesis"; Dieter Seebach et al; Laboratorium fur Organisch Chemie der Eidenossischen Technischen Hochschule; Pages 85-126.
	"Dietary Nonprotein calories and cerebral infarction size in rats"; Claudia Robinson et al; Stroke, Vol. 23, No. 4; April 1992; Pages 564-568.
	"Hypoxia and β -hydroxybutyrate acutely reduce glucose extraction by the brain in anesthetized dogs"; Albert S. Y. Change et al; Can J Poyiol Pharmacol, Vol. 71; 1993; Pages 465-472.
	" γ -Hydroxybutyrate: Cerebral metabolic, Vascular, and Protective effects"; Alan A. Artru et al; J Neurochem. Vol. 35, No. 5; 1980; Pages 1114-1119.
	"Effect of sodium hydroxybutyrate on the cerebral circulation and regional vasomotor reflexes"; E.A. Bendikov et al; Plenum Publishing Corporation; 1980; Pages 1287-1292.
	"Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease"; S. Hoyer; Acta Neurol Scand, Suppl. 165; 1996; Pages 18-24.
	"The ins and outs of amyloid- β "; Konrad Beyreuther et al; Nature, Vol. 389; 16 October 1997; Pages 677-678.
	"Metabolism of (R,S)-1,3-butanediol acetoacetate esters, potential parenteral and enteral nutrients in conscious pigs"; Sylvain Desrochers et al; The American Physiological Society; 1995; Pages 660-667.
	"The Gibbs-Donnan Near-equilibrium System of Heart"; Takashi Masuda et al; The Journal of Biological Chemistry, Vol. 265, No. 33; 25 November 1990; Pages 20321-20344.
	"Nutritional and metabolic studies in humans with 1,3-butanediol"; Richard B. Tobin et al; Federation Proceedings Vol. 34, No. 12; November 1975; Pages 2171-2176.
	"Utilization of 1,3-Butanediol and Nonspecific Nitrogen in Human Adults"; Constance Kies et al; Nebraska Agriculture Research Station Journal No. 3489; Pages 1115-1163.
	"Alzheimer's Disease: Genotypes, Phenotype, and Treatments"; Dennis J. Selkoe; Science, Vol. 275; 31 January 1997; Pages 630-631.
	"The β/α Peak Height Ratio of ATP"; Kieran Clarke et al; The Journal of Biological Chemistry, Vol. 271, No. 35, 30 August 1996; Pages 21142-21150.
	"Control of Glucose Utilization in Working Perfused Rat Heart"; Yoshishiro Kashiwaya et al; The Journal of Biological Chemistry, Vol. 269, No. 41; 14 October 1994; Pages 25502-25514.

*Examiner		Date Considered	
-----------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

[illegible]

Date Considered

811551